Akouos, Inc.
Akouos is a precision genetic medicine company focused on developing targeted gene therapies for inner ear disorders, aiming to restore and preserve hearing through innovative AAV vector-based treatments. Their mission is to address the high unmet need in hearing loss treatment by leveraging advances in genetics and gene therapy, with a focus on personalized medicine for sensorineural hearing loss.
Industries
Nr. of Employees
medium (51-250)
Akouos, Inc.
Patents
Compositions and methods for treating non-age-associated hearing impairment in a human subject
US-12305191-B2
View DetailsCompositions and methods for treating non-age-associated hearing impairment in a human subject
US-12264317-B2
View DetailsCompositions and methods for treating non-age-associated hearing impairment in a human subject
US-12077773-B2
View Details
Compositions and methods for treating non-age-associated hearing impairment in a human subject
US-12305191-B2
View DetailsCompositions and methods for treating non-age-associated hearing impairment in a human subject
US-12264317-B2
View DetailsCompositions and methods for treating non-age-associated hearing impairment in a human subject
US-12077773-B2
View DetailsProducts
Gene therapy candidate for otoferlin-mediated hearing loss
AAV-based gene therapy program designed to deliver a functional copy of the otoferlin gene to cochlear hair cells with the goal of restoring neurotransmitter release and hearing function following a single intracochlear administration; advanced to Phase 1/2 clinical testing.
AAV-mediated local anti-VEGF expression candidate for vestibular schwannoma
AAV-based program intended to deliver DNA encoding an anti-VEGF protein to the inner ear/tumor environment to achieve local therapeutic protein expression aimed at slowing or reversing vestibular schwannoma growth while limiting systemic exposure; advanced to Phase 1/2 clinical testing.
Gene therapy candidate for otoferlin-mediated hearing loss
AAV-based gene therapy program designed to deliver a functional copy of the otoferlin gene to cochlear hair cells with the goal of restoring neurotransmitter release and hearing function following a single intracochlear administration; advanced to Phase 1/2 clinical testing.
AAV-mediated local anti-VEGF expression candidate for vestibular schwannoma
AAV-based program intended to deliver DNA encoding an anti-VEGF protein to the inner ear/tumor environment to achieve local therapeutic protein expression aimed at slowing or reversing vestibular schwannoma growth while limiting systemic exposure; advanced to Phase 1/2 clinical testing.
Services
No-charge program providing comprehensive multigene testing and genetic counseling to help identify genetic causes of sensorineural hearing loss; available to providers in selected countries.
Curated resources for advocacy organizations, genetic counselors, providers, and patients including presentations, posters, clinical study information, and external advocacy links.
Design and conduct of early-stage clinical trials (Phase 1/2) for gene therapy candidates targeting genetic and non-monogenic inner ear disorders.
No-charge program providing comprehensive multigene testing and genetic counseling to help identify genetic causes of sensorineural hearing loss; available to providers in selected countries.
Curated resources for advocacy organizations, genetic counselors, providers, and patients including presentations, posters, clinical study information, and external advocacy links.
Design and conduct of early-stage clinical trials (Phase 1/2) for gene therapy candidates targeting genetic and non-monogenic inner ear disorders.
Expertise Areas
- Inner ear gene therapy
- AAV vector and capsid engineering
- Targeted inner ear drug delivery
- Preclinical development and animal models
Key Technologies
- Adeno-associated viral (AAV) vectors
- Capsid engineering (Anc80-like variants)
- Intracochlear / transcanal delivery
- Multigene genetic testing panels (~300 genes)